Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT00053196
First received: January 27, 2003
Last updated: September 27, 2013
Last verified: September 2013

January 27, 2003
September 27, 2013
December 2002
November 2006   (final data collection date for primary outcome measure)
Treatment-related mortality [ Time Frame: 6 months post transplant ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00053196 on ClinicalTrials.gov Archive Site
  • Per cent donor chimerism [ Time Frame: 30, 60, 90, 180 days post transplant ] [ Designated as safety issue: No ]
  • Disease-free survival [ Time Frame: 12 months up to 5 years post study entry ] [ Designated as safety issue: No ]
  • Graft-versus-host disease incidence [ Time Frame: 6 months post transplant ] [ Designated as safety issue: Yes ]
  • Response Rates [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation

RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapy after the transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well donor bone marrow or peripheral stem cell transplant works in treating patients with relapsed hematologic cancer after treatment with chemotherapy and autologous stem cell transplant.

OBJECTIVES:

  • Determine the feasibility of non-myeloablative allogeneic hematopoietic stem cell transplantation by demonstrating that the risk of treatment-related mortality during the first 6 months is an acceptable rate of less than 40% in patients with relapsed hematologic malignancies after prior high-dose chemotherapy and autologous stem cell transplantation.
  • Determine the response rates (disease-specific partial and complete response) in patients treated with this regimen.
  • Determine the 6-month and 12-month probabilities of response in patients treated with this regimen.
  • Determine the distribution of time-to-progression in patients responding to this regimen.
  • Determine the percent donor chimerism in patients treated with this regimen.
  • Determine the risk of acute and chronic graft-vs-host disease in patients treated with this regimen.
  • Determine the toxic effects of this regimen in these patients.
  • Determine the disease-free and overall survival of patients treated with this regimen.

OUTLINE: This is an open-label study.

  • Preparative Regimen: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours every 6 hours (for a total of 8 doses) on days -4 and -3.
  • Graft vs Host Disease (GVHD) Prophylaxis: Patients who have an HLA-identical donor receive oral (or IV if unable to tolerate oral administration) tacrolimus twice daily on days -1 to 90 followed by a taper^* until day 150 and methotrexate IV on days 1, 3, and 6. Patients with a matched related or matched unrelated donor receive oral (or IV if unable to tolerate oral administration) tacrolimus twice daily on days -1 to 180 followed by a taper^* as tolerated; methotrexate IV on days 1, 3, 6, and 11; oral mycophenolate mofetil twice daily on days -2 to 60 followed by a taper; and rabbit anti-thymocyte globulin IV over 4-6 hours on days -4 to -1 (for a total of 4 doses).

NOTE: *Tacrolimus may be tapered on days 60-90 if donor chimerism of CD3+ cells is less than 50% at day 60 or patient has progressive disease

  • Allogeneic Stem Cell Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 7 and continuing until blood counts recover.
  • Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.

Patients are followed within 2-3 months, every 3 months for 2 years, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 20-80 patients will be accrued for this study within 10-40 months.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myeloproliferative Neoplasms
  • Biological: anti-thymocyte globulin
    2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
  • Biological: G-CSF
    5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
    Other Name: filgrastim
  • Drug: busulfan
    0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
  • Drug: fludarabine phosphate
    30 mg/sq m/day IVBP over 30 min Days -7 thru -3
  • Drug: methotrexate
    5 mg/sq m/day IV infusion Days 1, 3, & 6 for HLA-identical donor transplants and Days 1, 3, 6, & 11 for MUD & 9/10 related donor transplants
  • Drug: mycophenolate mofetil
    15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
  • Drug: tacrolimus
    target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
  • Procedure: allogeneic cell transplantation
    2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
  • Drug: allopurinol
    300 mg/day PO Days -8 thru -1
Experimental: Non myeloblative allogeneic transplant
Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
Interventions:
  • Biological: anti-thymocyte globulin
  • Biological: G-CSF
  • Drug: busulfan
  • Drug: fludarabine phosphate
  • Drug: methotrexate
  • Drug: mycophenolate mofetil
  • Drug: tacrolimus
  • Procedure: allogeneic cell transplantation
  • Drug: allopurinol

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
82
August 2010
November 2006   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed hematologic malignancy, including one of the following:

    • Chronic lymphocytic leukemia (CLL)

      • Absolute lymphocytosis greater than 5,000/mm^3
      • Lymphocytes must appear morphologically mature with less than 55% prolymphocytes
      • Lymphocyte phenotype with expression of CD19 and CD5
    • Prolymphocytic leukemia (PLL)

      • Morphologically confirmed
      • Absolute lymphocytosis greater than 5,000/mm^3
      • More than 55% prolymphocytes
    • Non-Hodgkin's lymphoma or Hodgkin's lymphoma

      • Any WHO histologic subtype allowed except mantle cell lymphoma
      • Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping
      • No bone marrow biopsy as the sole diagnostic means for follicular lymphoma
    • Multiple myeloma

      • Active disease requiring treatment
      • Durie-Salmon stage I, II, or III
    • Acute myeloid leukemia

      • Documented control (i.e., less than 10% bone marrow blasts and no circulating blasts)
    • Myelodysplastic syndromes

      • Documented disease by WHO criteria
  • Must have evidence of relapse/progression at least 6 months after prior high-dose chemotherapy with autologous hematopoietic stem cell support
  • Absence of CD23 expression for CLL or PLL allowed provided there is no morphologic evidence of mantle cell lymphoma
  • Availability of any of the following donor types:

    • HLA-identical sibling (6/6)
    • 9/10 matched related donor by high-resolution molecular typing at HLA A, B, C, DRB1, and DQB1 loci

      • Only a single mismatch at one class I or II allele allowed
    • 10/10 matched unrelated donor by high-resolution molecular typing at HLA A, B, C, DRB1, and DQB1 loci
  • No syngeneic donors

PATIENT CHARACTERISTICS:

Age

  • Under 70

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • See Disease Characteristics

Hepatic

  • Bilirubin no greater than 3 times upper limit of normal (ULN)
  • AST no greater than 3 times ULN

Renal

  • Creatinine clearance at least 40 mL/min

Cardiovascular

  • LVEF at least 30% by MUGA

Pulmonary

  • DLCO greater than 40%
  • No symptomatic pulmonary disease

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No uncontrolled diabetes mellitus
  • No active serious infection
  • No known hypersensitivity to E. coli-derived products

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • More than 4 weeks since prior radiotherapy

Surgery

  • More than 4 weeks since prior surgery
Both
up to 69 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00053196
CDR0000269301, U10CA031946, CALGB-100002
No
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Study Chair: Asad Bashey, MD, PhD University of California, San Diego
Alliance for Clinical Trials in Oncology
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP